IONSIonis Pharmaceuticals, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 17157
Ticker: IONS
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 1991-05-17
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: IONS

Detail

Enriched 2026-08-14 20:47

Market cap: $9,394,399,722.66
Shares outstanding (class): 166,184,322
Shares outstanding (weighted): 166,184,322
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 1,402
Location: CARLSBAD, CA
Homepage: https://www.ionis.com
Description: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Market cap and share counts drift.

Funds holding this security

247 funds · 255 positions · $3.10B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$375.09M	0.02%	4,995,141 NS	FIGI
SMALLCAP World Fund Inc SMALLCAP World Fund Inc	—	$334.76M	0.41%	4,458,145 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$271.71M	0.17%	3,618,441 NS	FIGI
T. Rowe Price Mid-Cap Growth Fund, Inc. T. ROWE PRICE MID-CAP GROWTH FUND, INC.	—	$207.30M	0.92%	2,760,687 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$152.09M	0.39%	2,025,434 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$135.78M	0.17%	1,808,172 NS	FIGI
Tweedy, Browne International Value Fund Tweedy, Browne Fund Inc.	—	$130.89M	3.17%	1,743,125 NS	FIGI
Growth Fund AMERICAN FUNDS INSURANCE SERIES	—	$125.77M	0.25%	1,674,900 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$90.52M	1.11%	1,205,549 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$85.07M	1.14%	1,132,906 NS	FIGI
iShares Russell Mid-Cap Growth ETF iShares Trust	IWP	$74.18M	0.40%	987,917 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$66.29M	0.61%	882,823 NS	FIGI
JPMorgan Mid Cap Growth Fund JPMorgan Trust II	—	$60.57M	0.53%	806,672 NS	FIGI
Franklin Dynatech Fund Franklin Custodian Funds	—	$60.07M	0.24%	800,000 NS	FIGI
Nomura Mid Cap Growth Fund IVY FUNDS	—	$45.55M	1.52%	606,560 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERIONS
FIGI_COMPOSITEBBG000JH6683
FIGI_SHARE_CLASSBBG001SB7RD1
CIK0000874015
ISINUS4622221004
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Ionis Pharmaceuticals is a biopharmaceutical company focused on RNA-targeted therapeutics, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.